Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3437]
News [7962]
Articles [64]
Editorials [9]
Conferences [213]
elearning [49]
ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
ASH 2012: Engineered immune cells produce complete response in child with an aggressive paediatric leukaemia
ASH 2012: Engineered immune cells produce complete response in child with an aggressive paediatric leukaemia
ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy
ASH 2012: First curative treatment for acute promyelocytic leukaemia that does not include chemotherapy
ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic leukaemia
ASH 2012: Ibrutinib promotes high response rate in treatment naïve and relapsed or refractory chronic lymphocytic...
SABCS 2012: Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer
SABCS 2012: Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast...
SABCS 2012: Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment
SABCS 2012: Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment
SABCS 2012: Adjuvant bevacizumab does not improve invasive disease-free survival in triple-negative breast cancer
SABCS 2012: Adjuvant bevacizumab does not improve invasive disease-free survival in triple-negative breast cancer
SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit
SABCS 2012: Extending adjuvant trastuzumab treatment time provided no additional benefit
Women with higher carotenoid levels have reduced risk of breast cancer
Women with higher carotenoid levels have reduced risk of breast cancer
SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin treatment
SABCS 2012: HDAC inhibitors sensitised triple-negative breast cancer cells to PARP inhibition and cisplatin...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation